^
BIOMARKER:

MYCN amplification

i
Other names: MYCN, MYCN Proto-Oncogene BHLH Transcription Factor, V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog, Class E Basic Helix-Loop-Helix Protein 37, N-Myc Proto-Oncogene Protein, BHLHe37, NMYC, Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene, Neuroblastoma MYC Oncogene, Oncogene NMYC, BHLHE37, MODED, N-Myc, ODED
Entrez ID:
Related biomarkers:
Phase 3
Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
Last update posted :
09/20/2021
Initiation :
11/05/2019
Primary completion :
11/01/2026
Completion :
11/01/2032
MYCN • CD34
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • vincristine • dacarbazine • melphalan • busulfan • Qarziba (dinutuximab beta) • thiotepa • cyclophosphamide intravenous • vindesine
Phase 1/2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
09/17/2021
Initiation :
05/27/2009
Primary completion :
05/01/2023
Completion :
05/01/2023
MYCN • FCGR3A
|
MYCN amplification
|
GD2-GD3 Vaccine
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
01/14/2019
Primary completion :
12/31/2021
Completion :
12/31/2021
MYCN
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • daunorubicin • melphalan • Unituxin (dinutuximab) • thiotepa • Leukine (sargramostim) • cyclophosphamide intravenous • dexrazoxane • isotretinoin oral
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
09/02/2021
Initiation :
08/01/2005
Primary completion :
08/01/2022
Completion :
08/01/2022
MYCN
|
MYCN amplification
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
08/25/2021
Initiation :
08/01/2011
Primary completion :
08/01/2022
Completion :
08/01/2022
MYCN
|
MYCN amplification
|
Danyelza (naxitamab)
Phase 3
Children's Oncology Group
Recruiting
Last update posted :
08/25/2021
Initiation :
05/09/2018
Primary completion :
09/30/2026
Completion :
09/30/2026
MYCN
|
MYCN amplification
|
Xalkori (crizotinib) • cisplatin • carboplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • melphalan • busulfan • Unituxin (dinutuximab) • thiotepa • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane • isotretinoin oral
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
08/25/2021
Initiation :
11/30/2020
Primary completion :
12/31/2022
Completion :
12/31/2022
MYCN
|
MYCN amplification
|
temozolomide • irinotecan • Unituxin (dinutuximab) • Leukine (sargramostim) • isotretinoin oral
Phase 2
Giselle SaulnierSholler
Recruiting
Last update posted :
08/23/2021
Initiation :
09/01/2015
Primary completion :
09/01/2027
Completion :
09/01/2032
MYCN • IL2
|
MYCN amplification
|
dasatinib • Nexavar (sorafenib) • Zykadia (ceritinib) • Zolinza (vorinostat) • isotretinoin oral
Phase 2
Giselle SaulnierSholler
Recruiting
Last update posted :
08/23/2021
Initiation :
03/29/2021
Primary completion :
03/01/2028
Completion :
03/01/2029
TP53 • MYC • MYCN
|
TP53 mutation • MYCN amplification
Phase N/A
Giselle SaulnierSholler
Available
Last update posted :
08/23/2021
MYCN
|
MYCN amplification
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
08/12/2021
Initiation :
06/22/2021
Primary completion :
06/22/2022
Completion :
06/22/2022
MYCN
|
MYCN amplification
|
carboplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • vincristine • topotecan • mesna • cyclophosphamide intravenous
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/22/2021
Initiation :
06/12/2017
Primary completion :
06/01/2023
Completion :
06/01/2023
MYCN
|
MYCN amplification
|
temozolomide • irinotecan • Danyelza (naxitamab) • Leukine (sargramostim)
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
07/13/2021
Initiation :
10/01/2016
Primary completion :
12/01/2021
Completion :
06/01/2022
MYC • MYCN
|
MYCN amplification • MYC expression
|
fimepinostat (CUDC-907)
Phase 2
Memorial Sloan Kettering Cancer Center
Not yet recruiting
Last update posted :
07/02/2021
Initiation :
07/15/2021
Primary completion :
06/15/2023
Completion :
06/15/2023
MYC • MYCN • CSF2
|
MYCN amplification
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
05/27/2021
Initiation :
08/06/2012
Primary completion :
05/25/2021
Completion :
05/25/2021
MYCN
|
MYCN amplification
|
Danyelza (naxitamab)
Phase 1/2
Y-mAbs Therapeutics
Recruiting
Last update posted :
05/25/2021
Initiation :
02/22/2019
Primary completion :
02/01/2022
Completion :
02/01/2022
MYC • MYCN
|
MYCN amplification
|
cisplatin
Phase N/A
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
05/24/2021
Initiation :
10/20/2011
Primary completion :
03/01/2022
Completion :
03/01/2024
MYCN • CD34
|
MYCN amplification • LDH elevation
|
cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • busulfan • thiotepa • ursodeoxycholic acid
Phase 1/2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
05/03/2021
Initiation :
12/01/2012
Primary completion :
12/01/2023
Completion :
12/01/2023
MYC • MYCN • CSF2
|
MYCN amplification
|
irinotecan • Danyelza (naxitamab)
Phase N/A
Memorial Sloan Kettering Cancer Center
Approved for marketing
Last update posted :
04/14/2021
MYCN
|
MYCN amplification
|
Danyelza (naxitamab)
Phase N/A
Children's Oncology Group
Active, not recruiting
Last update posted :
03/26/2021
Initiation :
10/01/2010
Primary completion :
09/28/2016
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • melphalan • busulfan • Azedra (iobenguane I 131) • cyclophosphamide intravenous • isotretinoin oral • peripheral blood stem cell transplantation
Phase N/A
Children's Oncology Group
Recruiting
Last update posted :
03/24/2021
Initiation :
11/06/2000
Primary completion :
01/01/2100
MYCN
|
MYCN amplification
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
03/19/2021
Initiation :
09/27/2019
Primary completion :
07/10/2022
Completion :
07/10/2024
MYC • MYCN • BRD4
|
MYCN amplification
|
BMS-986158
Phase N/A
Children's Oncology Group
Active, not recruiting
Last update posted :
03/05/2021
Initiation :
04/08/2013
Primary completion :
07/28/2015
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • melphalan • mesna • busulfan • Neupogen (filgrastim) • cyclophosphamide intravenous • peripheral blood stem cell transplantation
Phase 2
St. Jude Children's Research Hospital
Active, not recruiting
Last update posted :
02/24/2021
Initiation :
07/05/2013
Primary completion :
12/01/2021
Completion :
12/01/2023
MYCN • CSF2
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • cyclophosphamide intravenous • humanised dinutuximab (Hu14.18K322A) • isotretinoin oral • levetiracetam
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
01/29/2021
Initiation :
07/01/2003
Primary completion :
01/15/2021
Completion :
01/15/2021
MYCN • CSF2
|
MYCN amplification
|
temozolomide • irinotecan • Leukine (sargramostim) • isotretinoin oral
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
12/11/2020
Initiation :
01/23/2017
Primary completion :
06/01/2022
Completion :
06/01/2022
MYCN
|
MYCN amplification
|
Danyelza (naxitamab) • isotretinoin oral
Phase N/A
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
12/02/2020
Initiation :
11/01/2014
Primary completion :
11/01/2021
Completion :
11/01/2021
MYCN
|
MYCN amplification
|
Danyelza (naxitamab)
Phase N/A
Giselle SaulnierSholler
Active, not recruiting
Last update posted :
11/18/2020
Initiation :
06/01/2014
Primary completion :
06/01/2025
Completion :
06/01/2026
MYCN
|
MYCN amplification
Phase N/A
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
10/30/2020
Initiation :
09/01/2014
Primary completion :
09/01/2021
Completion :
09/01/2021
MYCN
|
MYCN amplification
Phase 3
St. Anna Kinderkrebsforschung
Recruiting
Last update posted :
10/23/2020
Initiation :
02/01/2002
Primary completion :
09/30/2021
Completion :
09/01/2026
MYCN • IL2
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • etoposide IV • vincristine • melphalan • Proleukin (aldesleukin) • busulfan • Qarziba (dinutuximab beta) • Neupogen (filgrastim) • cyclophosphamide intravenous
Phase 3
Children's Oncology Group
Active, not recruiting
Last update posted :
10/23/2020
Initiation :
11/05/2007
Primary completion :
02/27/2015
Completion :
02/27/2022
CD8 • MYCN • UGT1A1 • CD4
|
MYCN amplification • UGT1A1*1*1
|
cisplatin • carboplatin • doxorubicin hydrochloride • etoposide IV • topotecan • melphalan • Marqibo (vincristine liposomal) • thiotepa • Neupogen (filgrastim) • TevaGrastim (filgrastim biosimilar) • cyclophosphamide intravenous • isotretinoin oral • peripheral blood stem cell transplantation
Phase N/A
St. Jude Children's Research Hospital
Completed
Last update posted :
10/23/2020
Initiation :
11/04/2014
Primary completion :
08/23/2019
Completion :
08/23/2019
RB1 • MYCN
|
MYCN amplification • RB1 mutation
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
10/02/2020
Initiation :
01/01/2016
Primary completion :
01/01/2022
Completion :
01/01/2022
MYCN
|
MYCN amplification
|
Danyelza (naxitamab) • cyclophosphamide intravenous
Phase 2
European Organisation for Research and Treatmen...
Not yet recruiting
Last update posted :
05/25/2020
Initiation :
09/01/2020
Primary completion :
12/01/2028
Completion :
12/01/2028
TP53 • BRCA2 • MYCN
|
MYCN amplification
|
cisplatin • vincristine • Odomzo (sonidegib) • lomustine
Phase 2
Baylor College of Medicine
Completed
Last update posted :
03/27/2020
Initiation :
03/01/2007
Primary completion :
07/01/2009
Completion :
03/01/2015
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • etoposide oral • melphalan • cyclophosphamide intravenous
Phase 1/2
GlaxoSmithKline
Completed
Last update posted :
03/16/2020
Initiation :
03/28/2012
Primary completion :
04/13/2018
Completion :
07/29/2019
ER • MYCN • NUTM1
|
ER positive • MYCN amplification
|
molibresib (GSK525762)
Phase N/A
Baylor College of Medicine
Completed
Last update posted :
03/12/2020
Initiation :
06/01/2016
Primary completion :
02/05/2019
Completion :
02/05/2019
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • Leukine (sargramostim) • cyclophosphamide intravenous
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
02/28/2020
Initiation :
03/01/2014
Primary completion :
03/07/2019
Completion :
03/07/2019
MYC • MYCN
|
MYCN amplification
|
isotretinoin oral
Phase 3
Instituto de Investigacion Sanitaria La Fe
Recruiting
Last update posted :
10/18/2019
Initiation :
12/01/2011
Primary completion :
12/01/2021
Completion :
12/01/2031
MYCN
|
MYCN amplification
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
10/09/2019
Initiation :
08/01/2010
Primary completion :
10/31/2018
Completion :
10/31/2018
MYCN • CSF2
|
MYCN amplification
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
08/13/2019
Initiation :
08/12/2010
Primary completion :
09/13/2018
Completion :
09/13/2018
MYCN • CSF2
|
MYCN amplification
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
08/13/2019
Initiation :
08/12/2010
Primary completion :
09/25/2018
Completion :
09/25/2018
MYCN • CSF2
|
MYCN amplification
Phase N/A
Institut Curie
Recruiting
Last update posted :
04/09/2019
Initiation :
04/20/2018
Primary completion :
04/01/2025
Completion :
04/01/2026
MYCN
|
MYCN amplification
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
01/10/2019
Initiation :
04/02/2009
Primary completion :
01/07/2019
Completion :
01/07/2019
MYCN • CD34
|
MYCN amplification
|
vincristine • topotecan • cyclophosphamide intravenous
Phase 2
Fundació Sant Joan de Déu
Active, not recruiting
Last update posted :
07/31/2018
Initiation :
11/01/2015
Primary completion :
05/01/2019
Completion :
05/01/2019
MYCN
|
MYCN amplification
|
Unituxin (dinutuximab) • Leukine (sargramostim) • isotretinoin oral
Phase 1/2
National University Hospital, Singapore
Recruiting
Last update posted :
03/30/2018
Initiation :
10/03/2017
Primary completion :
08/15/2019
Completion :
08/15/2020
MYCN
|
MYCN amplification
Phase 1
Penn State University
Withdrawn
Last update posted :
11/24/2017
Initiation :
06/01/2009
Primary completion :
08/01/2010
Completion :
08/01/2010
MYC • MYCN • CTAG1B • CD4
|
MYCN amplification
Phase N/A
Sinobioway Cell Therapy Co., Ltd.
Recruiting
Last update posted :
03/14/2017
Initiation :
09/01/2016
Primary completion :
09/01/2020
Completion :
09/01/2020
MYCN
|
MYCN amplification
|
GD2-targeted CAR-T cells
Phase 3
University of Cologne
Completed
Last update posted :
02/06/2017
Initiation :
01/01/2007
Primary completion :
12/31/2016
Completion :
12/31/2016
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • topotecan • melphalan • isotretinoin oral • vindesine
Phase N/A
Children's Oncology Group
Completed
Last update posted :
05/19/2016
Initiation :
01/01/2012
Primary completion :
05/01/2016
Completion :
05/01/2016
MYCN
|
MYCN amplification
Phase N/A
Children's Oncology Group
Completed
Last update posted :
05/18/2016
Initiation :
06/01/2011
Primary completion :
05/01/2016
NTRK2 • MYCN
|
MYCN amplification • NTRK expression
Phase N/A
Children's Oncology Group
Completed
Last update posted :
05/18/2016
Initiation :
06/01/2007
Primary completion :
05/01/2016
Completion :
05/01/2016
MYCN
|
MYCN amplification
Phase N/A
Children's Oncology Group
Completed
Last update posted :
05/18/2016
Initiation :
07/01/2010
Primary completion :
05/01/2016
Completion :
05/01/2016
MYCN
|
MYCN amplification
Phase N/A
Children's Oncology Group
Completed
Last update posted :
05/18/2016
Initiation :
03/01/2012
Primary completion :
05/01/2016
MYCN • TGFB1
|
MYCN amplification
Phase N/A
Children's Oncology Group
Completed
Last update posted :
04/15/2016
Initiation :
05/01/2011
Primary completion :
04/01/2016
Completion :
04/01/2016
MYC • MYCN • ROR1
|
MYCN amplification • ROR1 expression
Phase N/A
Gesellschaft fur Padiatrische Onkologie und Ham...
Recruiting
Last update posted :
07/16/2015
Initiation :
01/01/2007
Primary completion :
12/01/2016
MYCN
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • vincristine • dacarbazine • topotecan • melphalan • Azedra (iobenguane I 131) • Neupogen (filgrastim) • isotretinoin oral • vindesine
Phase N/A
Children's Oncology Group
Completed
Last update posted :
05/12/2015
Initiation :
05/01/2011
Primary completion :
08/01/2011
Completion :
08/01/2011
MYCN
|
MYCN amplification
Phase 3
University of Leicester
Recruiting
Last update posted :
06/24/2014
Initiation :
12/01/2001
MYCN • CD44
|
MYCN amplification
|
carboplatin • etoposide IV • vincristine • melphalan • busulfan • Neupogen (filgrastim) • isotretinoin oral
Phase 2
Children's Oncology Group
Completed
Last update posted :
02/13/2014
Initiation :
04/01/2001
Primary completion :
09/01/2005
Completion :
01/01/2012
MYCN
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • vincristine • melphalan • thiotepa • Leukine (sargramostim) • Neupogen (filgrastim) • isotretinoin oral • peripheral blood stem cell transplantation
Phase 1
Children's Oncology Group
Completed
Last update posted :
02/13/2014
Initiation :
03/01/2004
Primary completion :
09/01/2006
Completion :
12/01/2013
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • melphalan • Neupogen (filgrastim) • isotretinoin oral • peripheral blood stem cell transplantation
Phase N/A
National Taiwan University Hospital
Last update posted :
11/18/2013
Initiation :
08/01/2013
Primary completion :
07/01/2014
Completion :
07/01/2014
ALK • MYCN
|
MYCN amplification • ALK mutation
Phase 2
Memorial Sloan-Kettering Cancer Center
Completed
Last update posted :
10/31/2013
Initiation :
08/01/1999
Primary completion :
09/01/2004
MYC • MYCN
|
MYCN amplification
|
etoposide oral • isotretinoin oral
Phase 1
Memorial Sloan-Kettering Cancer Center
Completed
Last update posted :
10/16/2013
Initiation :
06/01/2005
Primary completion :
04/01/2013
Completion :
04/01/2013
MYC • MYCN • CSF2
|
MYCN amplification
|
Leukine (sargramostim)
Phase 2
Children's Cancer and Leukaemia Group
Active, not recruiting
Last update posted :
09/20/2013
Initiation :
12/01/2004
MYC • MYCN
|
MYCN amplification
Phase 2
European Infant Neuroblastoma Study Group - 1999
Completed
Last update posted :
09/17/2013
Initiation :
07/01/1999
Completion :
03/01/2009
MYCN
|
MYCN amplification
|
carboplatin • doxorubicin hydrochloride • etoposide IV • vincristine • melphalan • busulfan • Neupogen (filgrastim)
Phase 3
Gesellschaft fur Padiatrische Onkologie und Ham...
Recruiting
Last update posted :
08/07/2013
Initiation :
10/01/2004
Primary completion :
12/01/2010
MYCN
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV • vincristine • dacarbazine • topotecan • melphalan • Azedra (iobenguane I 131) • Neupogen (filgrastim) • isotretinoin oral • vindesine
Phase 3
Children's Cancer and Leukaemia Group
Active, not recruiting
Last update posted :
08/02/2013
MYCN
|
MYCN amplification
|
carboplatin • doxorubicin hydrochloride • etoposide IV • vincristine • melphalan • busulfan • Neupogen (filgrastim)
Phase 2
Children's Cancer and Leukaemia Group
Withdrawn
Last update posted :
07/10/2013
Initiation :
07/01/2008
Primary completion :
07/01/2008
MYCN
|
MYCN amplification
|
topotecan
Phase 2
Memorial Sloan-Kettering Cancer Center
Completed
Last update posted :
06/28/2013
Initiation :
02/01/1994
Primary completion :
04/01/2005
Completion :
04/01/2005
MYC • MYCN
|
MYCN amplification
|
Leukine (sargramostim)
Phase 3
Children's Oncology Group
Completed
Last update posted :
05/17/2013
Initiation :
02/01/2001
Primary completion :
10/01/2007
MYCN • CD34
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • melphalan • Neupogen (filgrastim) • cyclophosphamide intravenous • isotretinoin oral • peripheral blood stem cell transplantation
Phase 2
Memorial Sloan-Kettering Cancer Center
Completed
Last update posted :
03/07/2013
Initiation :
06/01/2000
Primary completion :
01/01/2007
Completion :
01/01/2007
MYC • MYCN
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • etoposide IV • vincristine • topotecan • thiotepa • Leukine (sargramostim) • Neupogen (filgrastim) • isotretinoin oral • peripheral blood stem cell transplantation
Phase 1
Memorial Sloan-Kettering Cancer Center
Completed
Last update posted :
01/18/2013
Initiation :
03/01/1997
Primary completion :
01/01/2005
MYC • MYCN
|
MYCN amplification
Phase 1
Memorial Sloan-Kettering Cancer Center
Completed
Last update posted :
01/18/2013
Initiation :
11/01/2001
Primary completion :
01/01/2005
MYC • MYCN
|
MYCN amplification
Phase 2
Memorial Sloan-Kettering Cancer Center
Completed
Last update posted :
01/17/2013
Initiation :
07/01/2004
Primary completion :
11/01/2006
MYCN
|
MYCN amplification
|
Leukine (sargramostim) • isotretinoin oral
Phase 1
Malcolm Brenner
Completed
Last update posted :
07/27/2012
Initiation :
11/01/1999
Primary completion :
12/01/2004
Completion :
10/01/2009
MYC • MYCN • IL2
|
MYCN amplification